Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00572845
Other study ID # HM11352
Secondary ID
Status Terminated
Phase N/A
First received December 11, 2007
Last updated February 19, 2016
Start date January 2008
Est. completion date July 2010

Study information

Verified date February 2016
Source Virginia Commonwealth University
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine if there is a relationship between spasticity and relative changes in Basal Energy Expenditure in persons with spinal cord injury.


Description:

Obesity is at epidemic proportions in the population with spinal cord injury (SCI), and is likely the mediator of the metabolic syndrome in this special population. Recent literature reviews have suggested that obesity is present in > 67% of persons with SCI. Additionally, recent studies have demonstrated the causal relationship between adipose tissue accumulation and vascular inflammation, dyslipidemia, insulin resistance / glucose intolerance, hypertension and thromboemboli.

Obesity in SCI occurs because of acute and ongoing positive energy balance, i.e., greater caloric intake than energy expenditure. Total Daily Energy Expenditure (TDEE) in SCI is reduced primarily because of muscular atrophy and diminished muscular contraction; pharmacological treatment of spasticity possibly reduces energy expenditure (EE) even further, but has not been evaluated to date. TDEE is comprised of three components: Basal Energy Expenditure (BEE), Thermic Effect of Activity (TEA) and Thermic Effect of Food (TEF). Of the three, BEE contributes the greatest amount (65-75% TDEE) and is the most sensitive to changes in spasticity.

Dampening spasticity has been reported to increase weight gain and necessitate reduced caloric intake in a child with spastic quadriplegia. Similarly, athetosis in patients with cerebral palsy increased resting metabolic rate (RMR) as compared to control subjects with no athetotic movements. Although several studies have reported energy requirements for persons with neurodevelopmental disabilities, and even SCI, however, none have attempted to measure the metabolic effect of spasticity.


Recruitment information / eligibility

Status Terminated
Enrollment 20
Est. completion date July 2010
Est. primary completion date July 2010
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- C1-T10 SCI at least 1 year post injury

- Spasticity in the legs

- Veteran

Exclusion Criteria:

- Recent increase in spasticity

- Botox within 6 months

- Phenol within 2 years

- Prior surgery for spasticity

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label


Intervention

Other:
Weaning of Antispasticity Medication
Weaning of antispasticity medication over a three day period and then titration back to previous dose over a three day period.

Locations

Country Name City State
United States McGuire VA Medical Center Richmond Virginia

Sponsors (1)

Lead Sponsor Collaborator
Virginia Commonwealth University

Country where clinical trial is conducted

United States, 

References & Publications (13)

Bauman WA, Spungen AM, Wang J, Pierson RN Jr. The relationship between energy expenditure and lean tissue in monozygotic twins discordant for spinal cord injury. J Rehabil Res Dev. 2004 Jan-Feb;41(1):1-8. — View Citation

Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987 Feb;67(2):206-7. — View Citation

Buchholz AC, McGillivray CF, Pencharz PB. Differences in resting metabolic rate between paraplegic and able-bodied subjects are explained by differences in body composition. Am J Clin Nutr. 2003 Feb;77(2):371-8. — View Citation

Clasey JL, Gater DR. Body Composition Assessment in Adults with Spinal Cord Injury. Topics in Spinal Cord Injury Rehabilitation. 2007;12(4):8-19.

Cox SA, Weiss SM, Posuniak EA, Worthington P, Prioleau M, Heffley G. Energy expenditure after spinal cord injury: an evaluation of stable rehabilitating patients. J Trauma. 1985 May;25(5):419-23. — View Citation

Dickerson RN, Brown RO, Gervasio JG, Hak EB, Hak LJ, Williams JE. Measured energy expenditure of tube-fed patients with severe neurodevelopmental disabilities. J Am Coll Nutr. 1999 Feb;18(1):61-8. — View Citation

Gater DR Jr. Obesity after spinal cord injury. Phys Med Rehabil Clin N Am. 2007 May;18(2):333-51, vii. Review. — View Citation

Gater DR. Pathophysiology of obesity after spinal cord injury. Topics in Spinal Cord Injury Rehabilitation. 2007;12(4):20-34.

Gorgey AS, Gater DR. Prevalence of Obesity after Spinal Cord Injury. Topics in Spinal Cord Injury Rehabilitation. 2007;12(4):1-7.

Hemingway C, McGrogan J, Freeman JM. Energy requirements of spasticity. Dev Med Child Neurol. 2001 Apr;43(4):277-8. — View Citation

Penn RD. Intrathecal baclofen for severe spasticity. Ann N Y Acad Sci. 1988;531:157-66. — View Citation

Rodriguez DJ, Benzel EC, Clevenger FW. The metabolic response to spinal cord injury. Spinal Cord. 1997 Sep;35(9):599-604. — View Citation

Rodriguez DJ, Clevenger FW, Osler TM, Demarest GB, Fry DE. Obligatory negative nitrogen balance following spinal cord injury. JPEN J Parenter Enteral Nutr. 1991 May-Jun;15(3):319-22. — View Citation

* Note: There are 13 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Increase in Basal Energy Expenditure 7 days No
See also
  Status Clinical Trial Phase
Recruiting NCT06150729 - Study of Intramuscular Injections of OnabotulinumtoxinA to Assess Change in Disease Activity in Pediatric Participants With Spasticity Associated With Cerebral Palsy
Completed NCT02400619 - Shockwaves Therapy and Botulinum Toxin for the Treatment of Spasticity in Patients With Cerebral Palsy. A Cross Over RCT Phase 1
Completed NCT01945684 - A Randomized, Double Blind, Multi-center, Active Drug Controlled, Phase III Clinical Trial to Compare the Safety and Efficacy of DWP450 Versus Botox® in Treatment of Post Stroke Upper Limb Spasticity Phase 3
Completed NCT02261142 - Efficacy and Cost-effectiveness of Spasticity Treatment With Multifocal TENS N/A
Completed NCT01444794 - Adult Subjects Suffering From Lower Limb Spasticity Following Stroke
Terminated NCT02877836 - Functional MRI and DTI in the Preoperative Assessment of Dystonia N/A
Completed NCT02334683 - Compare Two Guidance Techniques for Botulinum Toxin Injections for the Treatment of Limb Spasticity and Focal Dystonia N/A
Completed NCT02170779 - Developing and Testing a Comprehensive MS Spasticity Management Program Phase 2
Recruiting NCT05674604 - Cryoneurolysis for Knee and Shoulder Pain in an Inpatient Setting
Not yet recruiting NCT05926596 - Leg Stretching Using an Exoskeleton on Demand for People With Spasticity N/A
Terminated NCT01712087 - Long-term Surveillance of the MedStream Programmable Infusion System
Completed NCT03906305 - Dry Needling and Bobath Treatment Clinical Effects Focused on Stroke Patients N/A
Completed NCT03302741 - Imaging of 3D Innervation Zone Distribution in Spastic Muscles From High-density Surface EMG Recordings Phase 4
Completed NCT02291159 - Effects of DNHS Technique in the Treatment of Upper Limb Spasticity and Function in Stroke N/A
Completed NCT01743651 - Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis Phase 3
Completed NCT01523210 - DTI Study of the Influence of Physiotherapy on Distribution of BoNT in Spastic Muscle N/A
Completed NCT02073513 - Kinesiotaping the Hand in Cerebral Palsy N/A
Completed NCT00607542 - Oral Baclofen Pharmacokinetics and Pharmacodynamics in Children With Spasticity Phase 1/Phase 2
Completed NCT00702468 - Evaluate the Maintenance of Effect After Long-term Treatment With Sativex® in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis Phase 3
Active, not recruiting NCT04815967 - Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity Phase 2/Phase 3